ArticleInfluenza and other respiratory viruses2025
Epidemiology and Burden of Human Metapneumovirus Among Italian Adults in Outpatient and Inpatient Settings, 2014-2025.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MRSA nasal carriage among Taiwanese senior high school students and a narrative review of local metadata.New microbes and new infections · 2026Article
- Resurgence of human metapneumovirus: an overview of past and current trends.Archives of microbiology · 2026Review
- Epidemiology and Burden of Human Metapneumovirus Among Italian Adults in Outpatient and Inpatient Settings, 2014-2025.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHuman metapneumovirus (hMPV) has been increasingly recognized as a major contributor to respiratory infections in all age groups. Owing to its recent discovery, available data on the burden of hMPV in adults are still scant and heterogeneous. Here, we aimed to explore the epidemiology, symptomatic profile, and mortality related to hMPV among Italian adults.
methodsWe performed an integrated analysis of several community-based and hospital-based studies conducted in Genoa (Italy) between 2014 and 2025. Adults aged ≥ 18 years prescribed with ≥ 1 molecular test for hMPV were eligible.
resultsOf 21,580 and 2671 adults included in the hospital-based and community-based studies, 376 and 117, respectively, tested positive for hMPV. Seasonal (November to April) hMPV detection rate was 4.4% (95% CI: 3.6%-5.2%) in the community-based and 2.4% (95% CI: 2.1%-2.6%) in the hospital-based studies. Most detections occurred during the spring months. Each 1-year increase in age was associated with a 1.1% increase in the odds of hMPV positivity (adjusted odds ratio [aOR] 1.011; 95% CI: 1.005-1.016). Clinical presentation of hMPV resembled that of the phylogenetically related respiratory syncytial virus. Among hMPV-positive inpatients, 7.3% (95% CI: 4.3%-11.5%) died during their hospital encounter. In-hospital mortality was associated with residency in long-term care facilities (aOR 8.73; 95% CI: 2.63-29.15) and cancer (aOR 4.51; 95% CI: 1.50-14.35).
conclusionshMPV is a common virological finding in outpatient and inpatient adults and is responsible for a measurable burden, especially among the most frail older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.